

Strategic partnership via series B financing

March 31st, 2020

Noile-Immune Biotech, Inc. and Binex Co.,Ltd (“Binex”)/BiGEN Co.,Ltd. (“BiGEN”) announce that they will build up a strategic partnership with each other via series-B financing.

Noile-Immune, a Tokyo-based biotech company developing CAR-T programs for the treatment of solid cancers, has completed series-B financing by a third-party allocation of new shares to Binex and BiGEN, and made a decision to establish a strategic partnership in the area of finance and business development with Binex and BiGEN. In order to secure the efficient partnership among parties, companies agreed to appoint one director and one observer representing Binex and BiGEN in the board of directors of Noile-Immune. In addition to series-B financing, Binex and BiGEN determined to financially support Noile-Immune by actively participating in next round financing of Noile-Immune to be arranged near future.

With this Series B financing, Noile-Immune will be able to strengthen the foundation of management base and accelerate Noile-Immune’s upcoming clinical trials and R&D.

About Binex Co.,Ltd.

Binex (053030, KQ) is a contract development and manufacturing organization located in S.Korea. It has provided full range services from cell line development to GMP manufacturing for both the drug substance and drug product. CDMO services offered by Binex covers sophisticated analytic services and cGMP manufacturing for IMPs and commercial products (mAb/recombinant protein), leading to successful approval for INDs and BLAs of clients’ project. For more information, please visit <http://www.binex.com>

About BiGEN Co.,Ltd.

BiGEN, a private biotech company located in S.Korea, is focusing on business development in the area of cell and gene therapy through the activities of the equity investment on promising biotech companies and establishment of a strategic collaboration with partner companies to achieve its goal of building up integrative healthcare chain. For more information, please visit <http://www.bi-gen.com>

About Noile-Immune Biotech, Inc.

Noile-Immune Biotech, Inc. is a private biotechnology company focused on the development of next generation CAR-T cells for the treatment of solid cancers. Noile-Immune's proprietary novel cell therapy platform, PRIME (PRoliferation-Inducing and Migration-Enhancing) technology expressing a particular combination of IL-7 and CCL19, is able to enhance anti-tumor potential by enabling accumulation of CAR-T cells, dendritic cells, and polyclonal host T cells specific to endogenous tumor antigens into the tumor site. In 2018, Takeda Pharmaceutical Company exclusively licensed Noile-Immune's original pipelines, NIB-102 and NIB-103. In 2019, Noile-Immune has developed steadily in collaboration with leading biotech companies, such as Adaptimmune Therapeutics and Autolus Therapeutics, for the co-development of next-generation TCR-T and CAR-T products respectively, incorporating PRIME technology. For more information, please visit <https://www.noile-immune.com/english/>